Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Although the study was not designed to assess sensor accuracy, the system performed as expected, showing similar results to previous animal studies, the company noted. The CBGM sensor lead ...

The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that ...

“We are thrilled with the results of this first in human clinical study, which establishes safety of the placement, usage and removal of the CBGM sensor lead. While neither the study nor prototype ...

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that ...

usage and removal of the CBGM sensor lead. While neither the study nor prototype system was designed to evaluate sensor accuracy, the system performed as expected with similar accuracy results as ...

Glucotrack's CBGM system represents the company's focus on the design, development, and commercialization of innovative technologies for diabetes care. However, the press release also contains ...

Williams, with nearly a quarter-century of experience in regulatory affairs and quality assurance for complex medical devices, is expected to play a critical role in advancing the company's continuous ...